tapebrief
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

PM · Q2 2025 Earnings

Philip Morris International

Reported July 22, 2025

30-second summary

Smoke-free products grew 15.2% to $4.16B and now account for 41% of revenue, with adjusted operating margin reaching 41.9%. Management raised currency-neutral adjusted EPS growth guidance to +11.5–13.5% and dollar-terms EPS growth to +13–15%, while flagging ZYN restocking as a near-term tailwind and FDA PMTA timing for IQOS US as a potential 2026 slip. The quarter reads as a step-change in confidence: pricing is holding combustibles flat-to-up, ZYN supply has normalized, and management is now talking about VEEV as a structural margin contributor alongside IQOS and ZYN.

Headline numbers

EPS

Q2 FY2025

$1.91

Revenue

Q2 FY2025

$10.14B

+7.1% YoY

Gross margin

Q2 FY2025

67.7%

Operating margin

Q2 FY2025

36.6%

Key financials

Q2 FY2025
MetricQ2 FY2025YoY
Revenue$10.14B+7.1%
EPS$1.91—
Gross margin67.7%—
Operating margin36.6%—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment performance

Q2 FY2025
SegmentQ2 FY2025YoY
Combustible Tobacco$5.858B+2.1%
Smoke-Free Products$4.161B+15.2%
Smoke-Free Adjusted Gross Profit2.902—

Platform metrics

Q2 FY2025
SegmentQ2 FY2025
HTU Market ShareAdjusted for distributor/wholesaler inventory movements
Total Smoke-Free Products UsersEstimated from NCPT tracker and offtake volume trends
Total IQOS UsersLegal age users with HTU daily consumption past 7 days

Profitability

Q2 FY2025
SegmentQ2 FY2025
Adjusted Operating Income Margin41.9%
Europe Adjusted Operating Margin47.2%
Net Debt to Adjusted EBITDA2.85x
Total Debt to Adjusted EBITDA3.10x

Other KPIs

Q2 FY2025
SegmentQ2 FY2025YoY
Europe$4.234B+8.7%
SSEA, CIS & MEA$2.926B+5.6%
EA, AU & PMI GTR$1.708B+2.1%
Americas$1.272B+12.7%

Management tone

Management's posture this quarter is materially more confident than the cautious-to-neutral framing PMI has used through prior smoke-free transition phases. Three specific shifts stand out.

From ZYN supply caution to commercial reactivation. Through the last several quarters, ZYN commentary centered on availability constraints and the limits on advertising and promotion. That tone flipped this quarter: "Indeed, June was growing 36% in terms of consumer of tech, according to Nielsen. If I look at the first two weeks of July, we are north of 37%. I think the market is a bit above 39%. So basically, we are going now in line with the market." Management is now pulling commercial levers — advertising, loyalty, restock — rather than rationing demand. The 800–840M can FY shipment target is being defended as a floor, not a ceiling.

From eVapor-as-side-bet to VEEV as a margin pillar. Management framed VEEV as a structural profitability story, citing H1 shipment volumes more than doubling with "increasingly profitable growth driven by Europe" and "driving further gross margin expansion." VEEV now holds the number one closed-pod position in six European markets, including Italy and Greece, and PMI is leveraging the IQOS umbrella for premium positioning — a meaningfully bigger commercial commitment than PMI has previously made about eVapor.

From PMTA timing optimism to explicit slip risk. On IQOS ILUMA US approval, management moved from "expected in H2" to: "we don't have a certainty that we will get this PMTA in 2025. And that could move, of course, to 2026." This is the one piece of clear caution in an otherwise bullish call — the US IQOS launch timeline is now openly bracketed into 2026.

H2 margin honesty. Management flagged that H2 will not repeat H1's smoke-free margin progression because of tougher prior-year device comps: "We expect strong margin to continue in H2, albeit without the device year-on-year comparison benefit." This is the right disclosure to make now — it removes the ability for skeptics to claim a "hidden cut" if H2 smoke-free margin growth decelerates.

Recurring themes management leaned on this quarter:

Smoke-free acceleration with multi-category synergies driving margin expansionZIN supply normalization unlocking demand and commercial reactivationCombustible resilience through pricing offsetting volume declinesICOS momentum in Europe post-flavor-ban recovery and emerging markets growthOperating leverage and cost efficiency offsetting commercial investmentsH1 outperformance setting stage for strong full-year EPS guidance raise

Risks management surfaced:

Indonesia illicit trade growth impacting legal volumes and expected to extend into H2Turkey regulatory supply chain disruption causing temporary volume/share loss with inventory write-downsH2 high combustible volume comparison headwinds and phasing dynamicsFDA workload constraints creating potential PMTA delay into 2026 for ICOS ILUMA US approvalIncreasing competitive intensity in heated tobacco category despite category leadership

What to watch into next quarter

ZYN US shipments tracking to 800–840M cans: Q3 needs to demonstrate sustained share recovery toward the ~39% market level cited by management. Watch the run-rate exit velocity.

Q3 HTU shipments landing in 38.5–39.5B range: the low end implies decelerating momentum; the high end suggests skew-to-Q4 IMS guidance is on track.

FDA PMTA decision on IQOS ILUMA US: any update during Q3 either confirms 2026 slippage or re-opens H2 2025 launch optionality. Material to the US smoke-free TAM story.

Smoke-free adjusted operating margin sequencing: H2 YoY progression will be smaller per management's own framing — watch whether the absolute margin level (41.9% adjusted OI margin company-wide in Q2) holds.

Combustible pricing power into H2: Turkey and Indonesia volume headwinds extend into H2; pricing must continue offsetting. Watch for any pricing fatigue language.

FY EPS guide trajectory: with currency-neutral guide raised to +11.5–13.5%, the bar for a Q3 raise is now higher. Either Q3 prints another raise or management signals the bar is set.

Sources

  1. Philip Morris International Q2 2025 press release / SEC filing — https://www.sec.gov/Archives/edgar/data/1413329/000141332925000145/glossaryselectfininfoandno.htm
  2. Philip Morris International Q2 2025 earnings call (prepared remarks and Q&A)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.